Proteo, Inc. (Proteo) is a clinical-stage drug development company and focuses to develop, promote and market pharmaceuticals and other biotech products. The Company's focus is on the development of anti-inflammatory treatments for diseases. The Company is focusing its research on the development of drugs based on the human protein Elafin. Proteo has obtained Orphan drug designations within the European Union for the use of Elafin in treatment of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension, as well as for the treatment of esophagus carcinoma. Proteo's pharmaceutical Elafin is a copy of a human anti-inflammatory substance. Proteo Biotech AG (PBAG) is the company's wholly owned subsidiary.